Reviewing Genocea Biosciences (NASDAQ:GNCAQ) & Prime Medicine (NYSE:PRME)

Genocea Biosciences (NASDAQ:GNCAQ) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Risk and Volatility

Genocea Biosciences has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Genocea Biosciences and Prime Medicine, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0	0	0	0	0.00
Prime Medicine	0	3	4	1	2.75

Prime Medicine has a consensus price target of $8.92, suggesting a potential upside of 57.82%. Given Prime Medicine’s stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Genocea Biosciences.

Earnings & Valuation

This table compares Genocea Biosciences and Prime Medicine”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Prime Medicine	$4.96 million	153.26	-$198.13 million	($1.56)	-3.62

Genocea Biosciences has higher earnings, but lower revenue than Prime Medicine.

Insider and Institutional Ownership

70.4% of Prime Medicine shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Genocea Biosciences and Prime Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Prime Medicine	N/A	-107.87%	-74.97%

Summary

Prime Medicine beats Genocea Biosciences on 8 of the 10 factors compared between the two stocks.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.